The Impact of a Human Breast Milk Supplement on Epigenetic and Cellular Markers

Inclusion Criteria: * Men and women of any ethnicity. * Age Range - 18 - 85 years (inclusive) * Participant must be able to comply with treatment plan and laboratory tests * Participant must be able to read, write, and speak English fluently * Participant must have an established primary care provider * Participant must be willing and able to consume 2 capsules per day throughout the duration of study period * Participant must have a mobile telephone and internet connection Exclusion Criteria: * Patients with a self-reported history of lactose intolerance * History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer. * Known immune system issues or immunodeficiency disease * History of viral illness which could be reactivated by immune downregulation * Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) disease * Diagnosis of a transient ischemic attack in the 6 months prior to screening * Participants infected with hepatitis C or HIV * Presence of active infection in previous 4 weeks * Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the Clinical Investigator would render a participant unsuitable to participate in the study * Unable or unwilling to provide required blood sample for testing * Current or previous use of known prescription immunomodulating products (e.g. glucocorticoids, TNF-alpha inhibitors) in the month prior to the start of the trial. * A known history of blood dyscrasias including coagulopathy * Current pregnancy, planned attempts to conceive during study period or sexually active females not using contraception, as well as lactating/nursing females * Any person deemed by Clinical Investigator as low likelihood of complying with study protocol (e.g. evidence of history of non-compliance, history of poor follow-up, multiple or complex scheduling conflicts). * Planned surgical procedure during study period * Participants who are actively engaged in weight-loss or have started any new medications during the duration of the trial that can potentially interfere with the study, as deemed appropriate by Primary Clinical Investigator.